Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Rating of “Buy” from Analysts

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have earned a consensus rating of “Buy” from the nine brokerages that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and two have given a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $16.00.

A number of analysts have issued reports on the company. Wolfe Research raised Inventiva to a “strong-buy” rating in a report on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research report on Wednesday, October 8th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $20.00 price target on shares of Inventiva in a report on Tuesday, September 30th. Guggenheim dropped their price target on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Finally, Wall Street Zen upgraded shares of Inventiva to a “hold” rating in a research report on Saturday, October 18th.

Inventiva Trading Up 1.3%

IVA stock opened at $7.15 on Friday. The business’s fifty day moving average price is $4.80 and its 200 day moving average price is $4.69. Inventiva has a 12-month low of $2.15 and a 12-month high of $7.98.

Institutional Investors Weigh In On Inventiva

Hedge funds have recently made changes to their positions in the business. Creative Planning acquired a new position in Inventiva in the 2nd quarter valued at $32,000. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Inventiva by 54.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock valued at $50,000 after acquiring an additional 5,843 shares in the last quarter. NewEdge Advisors LLC purchased a new stake in shares of Inventiva in the third quarter valued at about $116,000. Finally, Millennium Management LLC acquired a new position in shares of Inventiva during the third quarter worth about $649,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.